Werfel TA, Hicks DJ, Rahman B, Bendeman WE, Duvernay MT, Maeng JG, Hamm H, Lavieri RR, Joly MM, Pulley JM, Elion DL, Brantley-Sieders DM, Cook RS. Repurposing of a Thromboxane Receptor Inhibitor Based on a Novel Role in Metastasis Identified by Phenome-Wide Association Study. Mol Cancer Ther. 2020 Dec;19 Epub 2020 Oct 8. PMID: 33033174

Challa AP, Lavieri RR, Lippmann ES, Goldstein JA, Bastarache L, Pulley JM, Aronoff DM. EHRs could clarify drug safety in pregnant people. Nat Med. 2020 Jun 26. PMID: 32457445

Jerome RN, Joly MM, Kennedy N, Shirey-Rice JK, Roden DM, Bernard GR, Holroyd KJ, Denny JC, Pulley JM. Leveraging Human Genetics to Identify Safety Signals Prior to Drug Marketing Approval and Clinical Use. Drug Saf. 2020 Feb 28. PMID: 32112228

Challa AP, Lavieri RR, Lewis JT, Zaleski NM, Shirey-Rice JK, Harris PA, Aronoff DM, Pulley JM. Systematically Prioritizing Candidates in Genome-Based Drug Repurposing. Assay Drug Dev Technol. 2019 Nov/Dec;17(8). PMID: 31769998

Pulley JM, Rhoads JP, Jerome RN, Challa AP, Erreger KB, Joly MM, Lavieri RR, Perry KE, Zaleski NM, Shirey-Rice JK, Aronoff DM. Using What We Already Have: Uncovering New Drug Repurposing Strategies in Existing Omics Data. Annu Rev Pharmacol Toxicol. 2020 Jan 6;60. PMID: 31337270

Choby JE, Monteith AJ, Himmel LE, Margaritis P, Shirey-Rice JK, Pruijssers A, Jerome RN, Pulley J, Skaar EP. A Phenome-Wide Association Study Uncovers a Pathological Role of Coagulation Factor X during Acinetobacter baumannii Infection. Infect Immun. 2019 Mar;87(5). PMCID: PMC6479028

Pulley JM, Jerome RN, Shirey-Rice JK, Zaleski NM, Naylor HM, Pruijssers AJ, Jackson JC, Bernard GR, Holroyd KJ. Advocating for mutually beneficial access to shelved compounds. Future Med Chem. 2018 Jun 1;10(12):1395–1398. PMID: 29788759

Jerome RN, Pulley JM, Roden DM, Shirey-Rice JK, Bastarache LA, R Bernard G, B Ekstrom L, Lancaster WJ, Denny JC. Using Human “Experiments of Nature” to Predict Drug Safety Issues: An Example with PCSK9 Inhibitors. Drug Saf. 2018;41(3):303–311. PMCID: PMC5828879

Pulley JM, Jerome RN, Ogletree ML, Bernard GR, Lavieri RR, Zaleski NM, Hong CC, Shirey-Rice JK, Arteaga CL, Mayer IA, Holroyd KJ, Cook RS. Motivation for Launching a Cancer Metastasis Inhibition (CMI) Program. Targeted Oncology. 2018 Feb;13(1):61–68.

Pulley JM, Jerome RN, Zaleski NM, Shirey-Rice JK, Pruijssers AJ, Lavieri RR, Chettiar SN, Naylor HM, Aronoff DM, Edwards DA, Niswender CM, Dugan LL, Crofford LJ, Bernard GR, Holroyd KJ. When Enough Is Enough: Decision Criteria for Moving a Known Drug into Clinical Testing for a New Indication in the Absence of Preclinical Efficacy Data. Assay Drug Dev Technol. 2017 Dec;15(8):354–361. PMCID: PMC5731541

Pulley JM, Shirey-Rice JK, Lavieri RR, Jerome RN, Zaleski NM, Aronoff DM, Bastarache L, Niu X, Holroyd KJ, Roden DM, Skaar EP, Niswender CM, Marnett LJ, Lindsley CW, Ekstrom LB, Bentley AR, Bernard GR, Hong CC, Denny JC. Accelerating Precision Drug Development and Drug Repurposing by Leveraging Human Genetics. ASSAY and Drug Development Technologies. 2017 Apr;15(3):113–119